New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareNAD+ vs Livagen

NAD+ vs Livagen

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
NAD+
Anti-Aging & Longevity
Livagen
Summary
NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme found in all living cells that declines dramatically with age. It is critical for energy metabolism, DNA repair, and sirtuin activation. IV and subcutaneous NAD+ supplementation is used in anti-aging protocols and addiction recovery programs.
Livagen is a dipeptide bioregulator (Lys-Glu) developed by Professor Vladimir Khavinson, tissue-specific for the liver and thymus. It supports hepatocyte function, promotes liver cell regeneration, and modulates immune function via thymic activity. Research suggests benefits in chronic liver disease, hepatic aging, and immune restoration following liver damage.
Half-Life
Varies by route; IV provides direct cellular delivery
Short (minutes); gene-regulatory effects are sustained
Admin Route
IV, SubQ, Oral
SubQ, Oral
Research
Typical Dose
500–1000 mg
10 mg per day
Frequency
Daily for 4–10 days (loading), then monthly maintenance
Daily for 10–30 days
Key Benefits
  • Restored cellular energy production (ATP)
  • Sirtuin activation for longevity and metabolic regulation
  • Enhanced DNA repair capacity
  • Improved mitochondrial function and biogenesis
  • Cognitive clarity and mental energy
  • Reduced inflammation
  • Addiction withdrawal support (opioids, alcohol, benzodiazepines)
  • Improved sleep quality
  • Enhanced athletic endurance
  • Supports hepatocyte regeneration and liver tissue repair
  • Normalizes liver cell protein synthesis
  • Immune modulation via thymic activity
  • Potential benefits in chronic hepatitis and liver aging
  • Anti-aging effects on hepatic tissue
  • May support liver recovery after toxic insult or alcohol damage
  • Complementary to NAD+ and glutathione in liver health protocols
Side Effects
  • Flushing and warmth during IV infusion
  • Nausea during rapid IV administration
  • Chest tightness (from rapid infusion — slow the rate)
  • Injection site irritation (subcutaneous)
  • +1 more
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hepatotoxic effects reported at standard doses
Stacks With